{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9"},{"groupId":"OG001","value":"43.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Evaluable AL patients"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"title":"Evaluable HSCT patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"307"}],"units":"Participants"}],"description":"A bacteremia incidence is defined as an occurrence of at least 1 episode of true (centrally reviewed) bacteremia among Acute Leukemia (AL) and Hematopoietic stem cell transplantation (HSCT) patients.","groups":[{"description":"Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.\n\nlevofloxacin: Given PO or IV","id":"OG000","title":"Arm I (Levofloxacin)"},{"description":"Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.","id":"OG001","title":"Arm II (Standard of Care)"}],"paramType":"NUMBER","populationDescription":"All evaluable, and centrally reviewed AL and HSCT patients are reported. Ineligible patients and patients who withdrew of consent prior to treatment were excluded.","reportingStatus":"POSTED","timeFrame":"Up to 60 days after enrollment or receiving levofloxacin","title":"Comparison of the Percentage of Patients Having Bacteremia Incidence Between Levofloxacin vs. No Prophylaxis Arms","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}